PRECIGEN, INC. Payments to Acquire Other Investments
PRECIGEN, INC. (PGEN) reported Payments to Acquire Other Investments of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-02.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireOtherInvestments · last filed 2020-03-02
- PRECIGEN, INC. payments to acquire other investments for the quarter ending 2018-12-31 was $0.00.
- PRECIGEN, INC. payments to acquire other investments for the quarter ending 2018-09-30 was $0.00.
- PRECIGEN, INC. payments to acquire other investments for the quarter ending 2018-06-30 was $0.00.
- PRECIGEN, INC. payments to acquire other investments for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- PRECIGEN, INC. payments to acquire other investments for fiscal 2019 was $0.00.
- PRECIGEN, INC. payments to acquire other investments for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- PRECIGEN, INC. payments to acquire other investments for fiscal 2017 was $1.16M, a 49.70% decline from fiscal 2016.
- PRECIGEN, INC. payments to acquire other investments for fiscal 2016 was $2.31M, a 86.49% decline from fiscal 2015.
| Period end | Payments to Acquire Other Investments 3 month | Payments to Acquire Other Investments 6 month | Payments to Acquire Other Investments 9 month | Payments to Acquire Other Investments 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-02 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $0.00 derived: sum of 2 quarters · filed 2018-11-08 | $0.00 10-Q · filed 2018-11-08 | $0.00 derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2018-08-13 | $0.00 10-Q · filed 2018-08-13 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $0.00 derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $0.00 10-Q/A · filed 2018-08-13 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $0.00 derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $1.16M 10-K · filed 2020-03-02 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $0.00 derived: sum of 2 quarters · filed 2018-11-08 | $1.16M 10-Q · filed 2018-11-08 | $1.16M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2018-08-13 | $1.16M 10-Q · filed 2018-08-13 | $1.16M derived: sum of 3 quarters · filed 2019-03-01 | $2.30M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $1.16M 10-Q/A · filed 2018-08-13 | $1.16M derived: sum of 2 quarters · filed 2019-03-01 | $2.30M derived: sum of 3 quarters · filed 2019-03-01 | $3.47M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $1.14M derived: sum of 2 quarters · filed 2019-03-01 | $2.31M derived: sum of 3 quarters · filed 2019-03-01 | $2.31M 10-K · filed 2019-03-01 |
| 2016-09-30 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $2.31M derived: sum of 2 quarters · filed 2017-11-09 | $2.31M 10-Q · filed 2017-11-09 | $2.31M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $1.17M 10-Q · filed 2017-08-09 | $1.17M derived: sum of 3 quarters · filed 2018-03-01 | $3.35M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $0.00 10-Q · filed 2017-05-10 | $0.00 derived: sum of 2 quarters · filed 2018-03-01 | $2.18M derived: sum of 3 quarters · filed 2018-03-01 | $2.18M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $2.18M derived: sum of 2 quarters · filed 2018-03-01 | $2.18M derived: sum of 3 quarters · filed 2018-03-01 | $17.08M 10-K · filed 2018-03-01 |
| 2015-09-30 | $2.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $2.18M derived: sum of 2 quarters · filed 2016-11-09 | $17.08M 10-Q · filed 2016-11-09 | $36.58M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $14.90M 10-Q · filed 2016-08-09 | $34.40M derived: sum of 3 quarters · filed 2017-03-01 | $34.40M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $14.90M 10-Q · filed 2016-05-10 | $34.40M derived: sum of 2 quarters · filed 2017-03-01 | $34.40M derived: sum of 3 quarters · filed 2017-03-01 | $34.40M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $19.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $19.50M derived: sum of 2 quarters · filed 2017-03-01 | $19.50M derived: sum of 3 quarters · filed 2017-03-01 | $19.50M 10-K · filed 2017-03-01 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $0.00 derived: sum of 2 quarters · filed 2015-11-09 | $0.00 10-Q · filed 2015-11-09 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $0.00 10-Q · filed 2015-08-10 | ||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-11 | |||
| 2013-12-31 | $28.65M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |